Boston Family Office’s CRISPR Therapeutics CRSP Stock Holding History

Boston Family Office’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,763	Closed	-$332K	–	285
2025 Q1	$332K	Hold	9,763	–	–	0.02%	231
2024 Q4	$384K	Hold	9,763	–	–	0.03%	218
2024 Q3	$459K	Buy	9,763 +213	+2%	+$10.8K	0.03%	208
2024 Q2	$516K	Hold	9,550	–	–	0.04%	193
2024 Q1	$651K	Hold	9,550	–	–	0.05%	171
2023 Q4	$598K	Hold	9,550	–	–	0.05%	175
2023 Q3	$433K	Hold	9,550	–	–	0.04%	197
2023 Q2	$536K	Hold	9,550	–	–	0.04%	183
2023 Q1	$432K	Hold	9,550	–	–	0.03%	203
2022 Q4	$388K	Hold	9,550	–	–	0.03%	213
2022 Q3	$624K	Hold	9,550	–	–	0.06%	175
2022 Q2	$580K	Hold	9,550	–	–	0.05%	186
2022 Q1	$599K	Hold	9,550	–	–	0.04%	190
2021 Q4	$724K	Hold	9,550	–	–	0.05%	181
2021 Q3	$1.07M	Hold	9,550	–	–	0.08%	155
2021 Q2	$1.55M	Hold	9,550	–	–	0.11%	137
2021 Q1	$1.16M	Sell	9,550 -750	-7%	-$113K	0.09%	149
2020 Q4	$1.58M	Hold	10,300	–	–	0.12%	130
2020 Q3	$861K	Hold	10,300	–	–	0.08%	157
2020 Q2	$757K	Hold	10,300	–	–	0.07%	157
2020 Q1	$437K	Hold	10,300	–	–	0.05%	178
2019 Q4	$627K	Sell	10,300 -100	-1%	-$5.46K	0.06%	175
2019 Q3	$426K	Hold	10,400	–	–	0.04%	202
2019 Q2	$490K	Hold	10,400	–	–	0.05%	196
2019 Q1	$371K	Hold	10,400	–	–	0.04%	217
2018 Q4	$297K	Sell	10,400 -100	-1%	-$3.48K	0.04%	221
2018 Q3	$466K	Buy	10,500 +100	+1%	+$5.24K	0.05%	202
2018 Q2	$611K	Buy	10,400 +400	+4%	+$22.8K	0.07%	178
2018 Q1	$457K	Buy	+10,000	New	+$413K	0.05%	203

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boston Family Office's CRSP Position: Q2 2025 in Review

Boston Family Office sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 9,763 shares — an estimated $332K sold.

Boston Family Office first reported a position in CRSP in Q1 2018 and held it in 29 quarters. The position peaked at $1.58M in Q4 2020. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Boston Family Office reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Boston Family Office sold 9,763 CRISPR Therapeutics shares in Q2 2025, an estimated $332K.
Boston Family Office first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 29 quarters.
Boston Family Office's CRISPR Therapeutics position peaked at $1.58M in Q4 2020.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Boston Family Office's 13F filing for Q2 2025, filed 13 Aug 2025.